Immunotherapy combo shows promise against stomach cancer in early trial
NCT ID NCT04221555
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested adding the immunotherapy drug durvalumab to a standard chemotherapy regimen (docetaxel, oxaliplatin, S-1) before and after surgery in 68 patients with resectable stomach or gastroesophageal junction cancer. The main goal was to see how many patients had a complete disappearance of the tumor after treatment. The study also tracked how long patients remained cancer-free after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug) plus docetaxel, oxaliplatin, and S-1 (chemotherapy drugs)
What this could lead to
If successful, this combination could improve the chance of eliminating the tumor before surgery and delay cancer return after surgery.
What could go wrong
This is a small, early-phase trial (68 people) with no control group, so results may not be definitive. Immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Seoul, South Korea